Sydney-based company Inventia Life Science has announced a new distribution agreement with Biotron Healthcare.
Biotron Healthcare has obtained sales rights for Inventia Life Science’s RASTRUM platform to enter the Indian market.
RASTRUM is designed specifically for cell biology. It creates complex, miniaturised 3D cell cultures quickly by printing hydrogels and cells, helping scientists to create advanced cell models at high speed.
Inventia founder and CEO Dr Julio Ribeiro said, “India has been constantly developing in the last decade to become a global powerhouse for biomedical research. Through its large network of academic institutes, CROs and ever-growing pharmaceutical and biotechnology companies, it has positioned itself as a key player in the global healthcare sector.
"Our partnership with Biotron Healthcare PVT Ltd has been based on a high degree of professionalism and common values directed at the desire to make a positive difference on public health and the way that we identify and treat disease”.